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ABSTRACT 
 
The issue of “Healthy Ageing” has become a significant challenge due to the continuous grow 
of World Population Ageing. Advancing health and well-being into old age and ensuring 
supportive environments is a main objective of NATO’s Department of Economic and Social 
Affairs Population Division [1]. 
Natural antioxidants such as L-carnosine and melatonin have been successfully used as 
geroprotectors. They reduce the risk of developing ageing-related diseases which is one the 
main aspects of healthy ageing. New formulation of the existing APIs is a widely used 
approach to optimize their physicochemical properties. Carnosine underwent reactions with a 
number of organic acids resulting in the discovery of seven new salts. The obtained salts were 
characterized by X-ray powder diffraction and thermal analyses. The structures were 
determined using X-ray Powder Diffraction (XRPD). The carnosine salts with glycolic and 
succinic acids might be of higher interest since both components possess antioxidant activity 
and carnosine, when used as a nutraceutical is usually combined with other antioxidants. 
Thus, the new formulation of carnosine as a salt with an acid possessing antioxidant activity 
can enhance its biological activity. Melatonin was co-crystallized with a number of co-
formers from various chemical groups. Two new co-crystals of melatonin with DABCO and 
piperazine were obtained by using mechanochemical technique (kneading). The structure of 
melatonin-DABCO co-crystal was established from a single crystal obtained by 
recrystallization from dichloromethane. The structure of melatonin-piperazine was solved 
using XRPD. Though only one of the obtained co-crystals can find a direct application in 
Pharmaceutical industry (DABCO does not belong to the GRAS list), our results confirm the 
reactivity of melatonin in co-crystallization processes, and emphasizes the need to continue 
the search for an improved formulation. 
Key words: carnosine, melatonin, geroprotectors, crystal engineering, co-crystals, salts 
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Abstract 
La questione di un "sano invecchiamento" è diventato una sfida significativa a causa del 
continuo aumento dell’età della popolazione mondiale. L’obiettivo principale del 
Dipartimento per gli Affari Economici e Sociali della NATO Divisione per la Popolazione è 
quello di garantire il benessere e ambienti favorevoli con il progredire dell’età [0]. 
Antiossidanti naturali come la L-carnosina e la melatonina sono stati utilizzati con successo 
come geroprotettori. Riducono il rischio di sviluppo di malattie legate invecchiamento, che è 
uno degli aspetti principali di un invecchiamento sano. La nuova formulazione di API già 
esistenti è un approccio ampiamente utilizzato per l’ottimizzazione delle loro proprietà 
chimicho-fisiche. La reazione tra la Carnosina ed un certo numero di acidi organici, ha 
prodotto la formazione di sette nuovi sali organici. I sali ottenuti sono stati caratterizzati 
mediante da diffrazione da raggi X su polveri ed analisi termiche (TGA e DSC). Le strutture 
cristalline sono state determinate utilizzando diffrazione da raggi X su polveri (XRPD). I sali 
ottenuti con gli acidi glicolico e succinico potrebbero essere di interesse maggiore poiché 
entrambi i componenti possiedono attività antiossidante e la carnosina, quando utilizzata 
come nutraceutico è solitamente combinata con altri antiossidanti. Così, la nuova 
formulazione di carnosina come un sale con un acido che possiede attività antiossidante può 
migliorare la sua attività biologica e, di conseguenza, consentire il suo utilizzo come farmaco 
indipendente / nutraceutico. La melatonina, invece,  è stata co-cristallizzata con un numero di 
co-former. Due nuovi co-cristalli di melatonina con diazabiblicloottano (DABCO) e 
piperazina (PIP) sono stati ottenuti per via meccanochimica (kneading). La struttura cristallina 
del co-cristallo melatonina-DABCO è stato determinata da diffrazione da raggi X su cristallo 
singolo, cresciuti da soluzioni di diclorometano; mentre la struttura del co-cristallo 
melatonina-PIP è stata risolta con XRPD. Anche se solo uno dei co-cristalli ottenuti può 
trovare applicazione nell'industria farmaceutica (DABCO non appartiene alla lista GRAS), i 
nostri risultati confermano la reattività della melatonina in processi di co-cristallizzazione, e 
sottolinea la necessità di proseguire nella ricerca di formulazioni migliori. 
 
PAROLE CHIAVE: carnosina, melatonina, geroprotectors, ingegneria di cristallo, co-
cristalli, sali 
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1. INTRODUCTION 
1.1 HEALTHY AGEING AND GEROPROTECTORS 
Population ageing is such a phenomenon when the average age of people living in the given 
region increases because of the extension of life duration and/or birth rates decrease. The 
United Nations report [1] indicates that the currently observed population ageing reaches the 
highest rates ever and according to the provided prediction, the number of older people 
worldwide will exceed that of younger ones by 2050. The increase of life expectancy has 
become possible due to a number of important factors, for instance, improvements in 
nutrition, sanitary conditions, and medical care to mention a few. Therefore, the most highly 
developed countries are the ones that already face this phenomenon: in 2000 approximately 
20 percent of the population were people aged 60 or older and by 2050 it is expected that 
every third person will be at this age. Though in the less developed countries the amount of 
people in the same age group is significantly lower, a tendency of population ageing can also 
be observed [1]. 
Taking into account the fact that recent scientific and clinical advances have led to the 
increase of life longevity the issue how to live these years with an appropriate quality of life 
has become of paramount importance. Increasing life expectancy is accompanied by a higher 
danger of development of age-associated diseases (e.g. coronary heart disease, 
cerebrovascular disease, cancer, arthritis, dementia, cataract, osteoporosis, type II diabetes, 
hypertension, Alzheimer's disease, Parkinson’s disease, etc.) [2]. Obviously, all the illnesses 
mentioned above notably decrease quality of life. Thus, a new notion – “Healthy Ageing” 
emerged as a complex of strategies which have to be applied in order to avoid or, at least, to 
postpone the development of these diseases and, consequently, to improve the wellbeing of 
older people. 
Healthy ageing can be determined as a permanent process which is aimed at maintaining and 
protecting physical, social, and mental health that, as a result, will allow sustaining 
independence and a higher quality of life. The governments of Western countries apply a 
number of various policies and information campaigns to emphasize the relevance of healthy 
ageing. The increase of awareness on health self-management, the benefits of physical 
activity, the “right” lifestyle and preventative health strategies is one of the main goals 
pursued by the governments. To summarize, the fundamental aim of those information 
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campaigns is to make ageing individuals pay more attention on personal contribution to the 
maintenance of health and to initiate the “anti-ageing” technologies [3]. 
Anti-ageing medicine has recently emerged as a new branch of medicine first in the US and 
afterwards spread around the world. Nowadays it has become a continuously expanding 
multimillion-dollar industry. According to anti-ageing medicine, senescence is referred to as a 
disease since it affects the economic, social and personal wellbeing of a person. Moreover, it 
is assumed that ageing might be even “cured” by a combination of diverse approaches: from 
diet and food supplements to antioxidants, hormone replacement therapies, and stem cell 
therapies [3]. 
In order to “treat” or, at least, influence on ageing it is necessary to understand what stays 
behind this process. Despite the fact that a large number of theories explaining the nature of 
senescence exists none of them has been accepted yet [4]. However, the free radical theory 
which was proposed by Harman in 1956 [5] and modified by other authors has become the 
most accepted one [6]. The general idea of this theory can be described in the following way: 
as oxygen-derived free radicals possess high reactivity they can damage biological molecules 
such as lipids, proteins and DNA that results into their functional impairment. And since the 
oxidative lesion of the macromolecules mentioned above accumulates with age, the caused 
damage becomes irreversible [7]. Of course, no one will deny the fact that oxygen radicals 
play an important role in a large number of metabolic and physiological processes. Therefore, 
the equilibrium between free radicals production and their antioxidant-linked inactivation is 
essential to protect a person’s health [6]. Actually, there are a number of mechanisms within 
the organism to maintain the reactive oxidants at the desired level or to reduce/treat the 
possible damage they might cause (e.g. enzymes capable of inactivating reactive oxidants or 
enzymes that repair the oxidized DNA, proteins, lipids) [7]. Besides the endogenous 
enzymatic defensive mechanisms, the consumption of nutrient antioxidants plays a crucial 
role in the maintenance of oxidants-antioxidants equilibrium. Fruits and vegetables are 
usually considered to be the main source of dietary antioxidants. However, it is hardly 
possible to consume them in the recommended quantities every day to maintain the required 
levels of antioxidants in the blood. Probably, that is the reason why antioxidants have become 
widely used in dietary supplements [7]. 
1.2 L-CARNOSINE AND MELATONIN 
L-Carnosine (fig.1.2.1) is a dipeptide of amino acids β-alanine and L-histidine.  
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Fig 1.2.1 L-carnosine
 
Carnosine was first isolated and purified in 1900 [8]. It is found exclusively in animal tissues. 
Usually it is accumulated in vertebrate brain and muscles in amounts proportional to their 
functional activity [9]. There are particular enzymes - carnosine synthase and carnosinase that 
regulate the level of carnosine in the blood: the former is responsible for its synthesis, the 
latter – for hydrolysis. The numerous studies of carnosine biological activity showed that it is 
a potent natural hydrophilic antioxidant which preserves human tissues from oxidative stress 
and is extremely useful in brain function protection [8]. Carnosine works as a scavenger of 
hydroxyl and superoxide radicals and, even more efficiently, of the singlet oxygen molecule. 
It shows the ability to inhibit some of the biochemical changes that might be responsible for 
ageing and ageing-associated diseases (protein oxidation, glycation). Due to its biological 
activity, carnosine has been successfully employed to treat neurodegenerative diseases and to 
prevent accumulation of senescence-related oxidative lesion of the macromolecules [9].  
Melatonin (N-acetyl-5-methoxy-tryptaminem, fig. 1.2.2) was first isolated and described by 
Lerner in 1958 [10]. It is the pineal hormone produced from the essential amino acid 
tryptophan mainly during the night [11]. 
N
H
O
N
H
O
Fig 1.2.2 Melatonin
 
Melatonin plays a vital role in the regulation of circadian and seasonal changes in various 
aspects of physiology and neuroendocrine function. In other words, melatonin is responsible 
for the body internal timekeeping system and for the regulation of the sleep-wake cycle and 
seasonal adaptation. In addition to its main functions, melatonin is also a powerful free-
radical scavenger and wide-spectrum antioxidant. Like carnosine, melatonin in vitro 
scavenges hydroxyl and superoxide radicals and the singlet oxygen molecule, but, in contrast 
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to carnosine, it can also detoxify reactive nitrogen species. Besides its role as a direct 
scavenger, melatonin induces antioxidative enzymes (glutathione peroxidase, glutathione 
reductase, and catalase) and improves the effectiveness of the electron transport chain 
decreasing electron leakage and, as a result, free radicals generation [11]. All these properties 
allow melatonin to protect macromolecules (DNA, protein, lipids) from free radical damage. 
The investigations of melatonin influence on life span and longevity in rodents [12] and fruit 
flights [13] have been recently accomplished. In both cases the geroprotective effect of 
melatonin was observed. However, with ageing, the nocturnal synthesis of melatonin declines 
significantly in humans, which results into a deficit of this hormone [11].  
To sum up, both carnosine and melatonin play an essential role in human healthy life and the 
shortage of any of these antioxidants may result into oxidative damage of their DNA, lipids 
and proteins. Consequently, it leads to the accelerated senescence and may cause a higher risk 
of the development of ageing-related disease, particularly neurodegenerative ones 
(Parkinson’s disease and Alzheimer’s disease). Therefore, the increasing interest in 
consumption of antioxidants is not surprising. Currently both carnosine and melatonin are 
used as nutraceuticals usually in combination with each other or some other antioxidants. 
There can be several reasons to explain this approach. First, the producers may intend to 
introduce to a patient a number of various antioxidants at once. Second, there is a chance that 
neither carnosine nor melatonin possesses enough antioxidant activity to cause significant 
geroprotective effect. Finally, there is some evidence that carnosine and/or melatonin may be 
acting synergistically with other antioxidants [14].  
Another possible explanation why neither melatonin nor carnosine are commercialized as 
separate drugs may be the fact that no suitable formulation of these APIs have been found yet. 
Thus, we decided to investigate the solid-state properties of these antioxidants and, based on 
the obtained information, to try and develop new pharmaceutical formulations for them.  
1.3 CRYSTAL ENGINEERING 
The choice of an appropriate pharmaceutical formulation and/or a particular solid form of API 
is one of the most crucial aspects in the development of new drugs [15]. The application of 
crystal engineering approaches can be of use to solve this problem. Von Hippel explained in 
details the basics of crystal engineering using the term ‘molecular engineering’ in 1962 [16]. 
Subramanian et al. defined crystal engineering as “exploitation of non-covalent interactions 
between molecular or ionic components for the rational design of solid-state structures that 
 16 
 
might exhibit interesting electrical, magnetic, and optical properties” [17]. In our work crystal 
engineering approaches were used from the point of view of design of molecular solids in 
order to have a chance to influence on specific physicochemical properties of the investigated 
APIs.  
The increasing interest in a thorough investigation of solid-state properties of drugs can be 
explained by serious setbacks caused by insufficient understanding of them. A clear 
understanding of solid-state properties may be beneficial for both manufacturers (higher 
yields, lower expenses) and the customers (improved drug properties) [18]. A number of 
investigations should be done in the drug development process since the used API can exist in 
several crystal forms (polymorphs) [15]. But why the choice of the most suitable polymorphic 
form can be of paramount importance? It is critical that an optimal solid form must be chosen 
for production since it can drastically affect physicochemical characteristics (e.g. solubility, 
dissolution rate, melting point to mention a few) which, in turn, influence on their 
pharmaceutical activity, and pharmacodynamic properties. Stability of the formulated drug is 
another important issue since the chosen solid form may transform into another polymorph 
during formulation of the pharmaceutical or its storage. 
Nowadays design, formulation and characterization of multiple crystal forms, especially co-
crystals and molecular salts, have become one of the most widely studied areas in the broad 
field of crystal engineering [19]. Pharmaceutical co-crystals attracts scientists since they 
significantly diversify the amount of solid forms of APIs, can improve their physicochemical 
properties [15], and, finally, they satisfy the three criteria of patentability (novelty, non-
obviousness and utility) [20]. The latter is of high interest for the manufacturers since it 
allows covering their scientific and technological inventions using patent system. Patenting is 
a mechanism to promote research for society’s benefit: “it gives the right to exclude others 
from practicing a patented invention affords an economic incentive to the inventor, while the 
limited term of that exclusionary right ultimately delivers the invention into the public 
domain” [21]. Here is an example of possible benefits the producers of APIs may receive due 
to thorough investigations of solid-state properties of a new API and patenting of its particular 
crystal form. When a research team realizes that the newly obtained API possesses the 
desirable biological activity and can find an application in Pharmaceutical industry, it patents 
the chemical structure of this API (primary patent protection for a marketed pharmaceutical 
product). The following search for polymorphs, co-crystals, salts, hydrates and solvates of this 
API can be of interest. If any of the obtained crystal forms shows preferable physicochemical 
 17 
 
properties, the developer will receive additional options in patenting. On the one side, the 
novel solid forms of the API can be patented simultaneously with the chemical structure of 
API. This approach protects against other companies filing applications on the same solid 
forms and can serve as an additional obstacle for the development of technology that will 
allow circumventing the product intellectual property protection. On the other side, the 
patenting of the new crystal form can be postponed. This approach is more risky, but it can 
prolong the patent protection (the one for the solid form will still work after the core chemical 
structure patent expires) and, as a result, the patent holder may receive higher profits [21]. 
1.4 PHARMACEUTICAL SALTS AND CO-CRYSTALS 
Since both pharmaceutical salts and co-crystals find a wide application in Pharmaceutical 
industry it is important to understand the difference between them. The important difference 
between a salt and a co-crystal formation is the role they play in pre-formulation activities and 
chemical development of a drug. Salts and co-crystals can be considered to be at the opposite 
extremes of multi-component structures. A salt, as a formulation, is preferable for those APIs 
which are free acids or bases, since it can improve their crystallinity, solubility and stability; 
whereas a co-crystal serves as an alternative in case when a salt cannot be formed due to the 
absence of ionisable moieties in the API or when the obtained salts do not possess the proper 
solid state or required physicochemical properties [22]. 
The Compendium of Chemical Technology defines a salt as a “chemical compound 
comprising an assembly of cations and anions” [23]. Consequently, a pharmaceutical salt 
consists of an API which can be either cationic or anionic and of a counterion. To date, there 
is no generally accepted definition for a co-crystal. The definition “co-crystals are structurally 
homogeneous crystalline materials containing two or more components present in definite 
stoichiometric amounts” [24] seems to make sense in opinion. However, it is worth 
mentioning one important thing: components of co-crystal are discrete neutral molecular 
reactants solid at ambient temperature. This qualification allows distinguishing co-crystals 
from solvates and hydrates. One must be cautious since this clarification can be misleading: 
an API hydrate is not a co-crystal whereas a solid-state API hydrate can form a co-crystal 
with a solid co-former [25]. Consequently, a pharmaceutical co-crystal consists of an API and 
a co-former. Dario Braga et al. [19] defined a pharmaceutical co-crystal as “a multi-
component crystalline solid formed when the molecule of interest can be stoichiometrically 
crystallized with a co-former molecule so that the API retains its chemical nature, but the 
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resulting solid acts as a different functional material due to changes in solubility, morphology, 
thermal stability, hygroscopicity, etc.” An important issue is the fact that in order to be 
applicable as a part of a drug a co-former must be non-toxic. For this purpose, a list of 
Generally Regarded as Safe (GRAS) co-formers was formed [26]. 
The general approach to distinguish salts from co-crystals is based on charged or neutral 
molecular components. However, sometimes this task becomes quite complicate since there is 
a chance that during the co-crystallisation process a proton involved in the hydrogen-bonding 
interaction can be transferred from the donor (acid) to acceptor (base) resulting into a 
formation of a salt [20]. In order to have a better chance to predict the final product of 
interaction, an “empirical rule of two” may be useful. According to this rule, one should 
expect to obtain a salt when the difference between pKa values of the acid and conjugate acid 
of the base is equal to two or higher. Of course, there are some exceptions and it is important 
to realize the influence of environmental factors on the possible protonation [20]. 
Nonetheless, we applied this rule in our work and it appeared to be very helpful. 
In order to confirm the fact that the distinction between a co-crystal and a salt is a difficult 
task I decided to give two examples: a gabapentin salt with 2-hydroxybenzoic acid (fig. 1.4.1) 
and a gabapentin co-crystal with 3-hydroxybenzoic acid (fig. 1.4.2) described by Reddy et al 
[27]. 
 
Fig. 1.4.1 A gabapentin salt with 2-hydroxybenzoic acid 
H atoms not involved in hydrogen bonding have been omitted for clarity 
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From fig.1.4.1 it becomes clear that the transfer of proton (marked in green) from carboxylic 
group of salicylic acid to amino group of gabapentin took place and, correspondingly, the salt 
was formed. 
 
Fig. 1.4.2 A gabapentin co-crystal with 3-hydroxybenzoic acid 
H atoms not involved in hydrogen bonding have been omitted for clarity 
 
However, fig. 1.4.2 shows that the carboxylic group proton of 3-hydroxybenzoic acid (marked 
in green) was not transferred to the amino group of gabapentin. The protonation of amino 
group of gabapentin became possible due to intramolecular protonation of gabapentin: we can 
clearly see that in this solid form it exists as a zwitter-ion. 
1.5 SYNTHESIS OF CO-CRYSTALS 
Unlike salt formation wherein an acid is obviously required to make a salt upon a reaction 
with a base and vice versa, the process of co-crystals construction is more complex. 
Intermolecular interactions such as van der Waals interactions, pi-pi stacking interactions, and 
hydrogen bonding play crucial role in co-crystal formation. Thus, the task of crystal 
engineering is to alter these intermolecular interactions and, in this way, to influence the 
formation of non-covalent bonds, i.e. the crystal packing of a solid material [25]. The 
possibility to obtain a co-crystal is to a great extent based on reliable patterns of directional 
non-covalent interactions, which keep molecules together generating zero-, one-, two- or 
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three-dimensional aggregates in the crystal [28,29]. These patterns are called supramolecular 
synthons – the term introduced by Desiraju [30] as “structural units within supermolecules 
which can be formed and/or assembled by known conceivable synthetic operations involving 
intermolecular interaction”. In other words, supramolecular synthons are spatial arrangements 
of intermolecular interactions and the task of crystal engineering is to identify and to apply 
them in the design of co-crystals [31]. 
The fig. 1.5.1 represents typical synthons employed in pharmaceutical co-crystals formation. 
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Fig. 1.5.1 Representative supramolecular synthons 
 
Synthons 1 and 2 are homosynthons exhibited by carboxylic acid and amide dimers, 
respectively; synthon 4 is an example of heterosynthons formed by acid-amide dimers. 
Synthon 3 has strong N–H⋅⋅⋅O and O–H⋅⋅⋅N interactions whereas 5 is a less favoured synthon 
with one weak C–H⋅⋅⋅O and one strong O–H⋅⋅⋅N hydrogen bond [31]. 
Despite the fact that many different approaches to obtain co-crystals have been reported to 
date, the most common of them can be to a certain extent united into two main groups: 
formation method based on solution and grinding [25,32]. Solution method is of particular 
interest since it is the only way to grow a single crystal and to fully characterize it using single 
crystal X-ray diffraction testing. Solution methods comprise the following techniques: 
evaporation of a heterometric solution, reaction crystallisation, and cooling crystallisation. 
Evaporation of stoichiometric solutions is one of the most applicable approaches for co-
crystal screening. The technique is based on reactant solubility levels in a particular solvent: if 
both reagents possess similar solubilities in the used solvent they are mixed at equimolar 
amounts and a 1:1 pure co-crystal can be obtained after slow evaporation of the solvent from 
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the solution. A number of co-crystals have been obtained using this approach [33]. Reaction 
crystallisation method is applied when reagents have different solubilities in the used solvent. 
For such cases co-crystallisation using evaporation of an equimolar solution cannot be 
employed since the supersaturation of a less soluble reagent will occur earlier which can lead 
to the formation of its crystals while the second component will be still in solution. As a 
result, reactants can be crystallised separately or as a mixture with a co-crystal. Therefore, the 
reaction co-crystallisation method becomes helpful for such cases. It is performed by adding 
one of the reactants to a saturated solution of the other one. In this way the solution becomes 
supersaturated with respect to co-crystal. Cooling crystallisation technique is based on 
varying the temperature of the crystallisation system. This approach has a great potential for a 
large-scale of co-crystal production. In this method large amounts of starting materials and 
solvent are mixed in a reactor. Afterwards the mixture is heated to ensure both reagents are 
completely dissolved in the solvent. The next step is a controllable cooling of the system. 
When the temperature decreases, the solution becomes supersaturated with respect to a co-
crystal, its crystals start to precipitate [25]. 
Grinding methods consist of grinding and kneading. Grinding method represents a manual 
(using a mortar and a pestle) or mechanical (using a ball mill or a vibratory mill) mixing of 
the stoichiometric amounts of reagents which are expected to form a co-crystal. Kneading 
(liquid-assisted grinding, solvent-drop grinding, wet co-grinding) is similar to grinding with 
the only difference that minor amounts of solvent is added to the grinded mixture. However, 
considerable improvements in kinetics of co-crystal formation by grinding can in many cases 
be attained by the addition of a drop of the suitable solvent [34,35]. The main drawback of 
grinding method, in my point of view, is the fact that in order to characterize the obtained co-
crystal it is necessary either to recrystallise it to have a single crystal or to solve the structure 
from X-ray powder diffraction which is pretty difficult. Recrystallization of the co-crystal 
sometimes leads to its separation to the starting materials. 
Besides these methods, a number of new co-crystallisation approaches have recently emerged 
(co-crystallisation using supercritical fluid, hot-stage microscopy, and ultrasound-assisted co-
crystallisation) [25]. 
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2. EXPERIMENTAL PART 
All reagents and solvents used in this work were purchased from Sigma-Aldrich and used 
without further purification. 
2.1 POLYMORPHIC SCREENING 
50 mg of L-carnosine were dissolved stirred in 4 mL of several aqueous mixtures of different 
organic solvents miscible with water (ethanol, methanol, acetone, propanol-2, and 
acetonitrile). Solutions were left to evaporate at room temperature, yielding microcrystalline 
powders. The obtained powders were analysed using X-ray powder diffraction. 
A similar procedure was used for Melatonin: 50 mg were dissolved in 4 mL of ethanol, 
methanol, dichloromethane, acetone, chloroform and water solutions. The solutions were left 
to evaporate at room temperature, yielding single crystals in all the vials but the one with 
water, where microcrystalline powder was formed. The obtained crystals were analysed using 
single crystal X-ray diffraction. 
2.2 SYNTHESIS USING SOLUTION METHODS 
50 mg of L-carnosine and 17 mg of Fumaric acid (1:1 stoichiometry) were dissolved in 3 mL 
of water; the solution was left to evaporate at room temperature, yielding microcrystalline 
powder of a monohydrated salt of fumaric acid and carnosine (Table 2.2.1). Using the same 
approach (slow evaporation from aqueous solutions using 1:1 stoichiometry) carnosine salts 
with adipic, glutaric, succinic, glycolic, salicylic and maleic acids were obtained. The only 
difference was the fact that evaporation process resulted into oil formations. These oils 
precipitated as microcrystalline powders of salts in 1-2 weeks. Thus, we obtained 
monohydrated salts of carnosine with succinic, salicylic, and maleic acids and anhydrous salts 
of carnosine with glutaric, adipic and glycolic acids. 
Table 2.2.1 Preparation of carnosine salts 
# Acid Quantity for 50 
mg of Carnosine 
Solvent Product 
1 Fumaric 25.5 mg H2O [Hcar]*[Hfum]*H2O 
2 Salicylic 30.5 mg H2O [Hcar]*[sal]*H2O 
3 Maleic 25.5 mg H2O [Hcar]*[Hmal]*H2O 
4 Glutaric 29 mg H2O [Hcar]*[Hglu] 
5 Succinic 26 mg H2O [Hcar]*[Hsuc]*H2O 
6 Glycolic 17 mg H2O [Hcar]*[gly] 
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The folic acid:carnosine salt was obtained using 1:2 ratio. This salt and the one with adipic 
acid are not listed in the table given above since there crystal structures have not been 
determined yet. 
2.3 SYNTHESIS USING GRINDING METHODS 
The co-crystals of melatonin with DABCO and piperazine were obtained by kneading 
experiments using some drops of ethanol. 50 mg of melatonin and 24 mg of DABCO or 18.5 
mg of piperazine correspondingly (1:1 stoichiometry in both cases) were ground using a 
Retsch MM400 grinder mill operated at a frequency of 20 Hz for 30 minutes adding a few 
drops of solvent. 
2.4 X-RAY POWDER DIFFRACTION 
Room temperature powder X-ray diffraction (PXRD) patterns were collected on two different 
diffractometers: on a Bruker D2 phaser X-ray diffractometer in the 2θ range from 3° to 37° 
using a Cu-Kα (λ=1.54 Å) source equipped with a LinxEye detector, nickel filter and operated 
at 30 kV and 10 mA and on a PANalytical X’Pert PRO automated diffractometer equipped 
with a X’celerator detector in the 2θ range 2.5–60° (step size 0.011, time/step 50 s, VxA 
40x40). Data analysis was carried out using the Panalytical X’pert Highscore Plus program. 
The identity between the bulk material obtained via the solution and solid-state processes was 
verified by comparing calculated and observed powder diffraction patterns. 
2.5 SINGLE CRYSTAL X-RAY DIFFRACTION 
Melatonin-DABCO single crystals were (fig. 3.2.5) obtained by slow evaporation after 
dissolving in dichloromethane a mechanochemically prepared co-crystal. X-ray single 
diffraction was conducted on Bruker D8 and X8 Apex II diffractometers equipped with 
MoKα X-ray sources and graphite monochromators. Multi-scan absorption correction 
(SADABS) was applied. Structure was solved by direct methods and refined using SHELX-
97. 
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2.6 DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
DSC measurements were performed for carnosine salts with a Perkin–Elmer Diamond. 
Samples (3–5 mg) were placed in hermetic aluminium pans. Heating was carried out at 5 °C 
min-1 for all samples. 
2.7 THERMAL GRAVIMETRIC ANALYSIS (TGA) 
TGA measurements of carnosine salts were performed using a Perkin-Elmer TGA7 in the 
temperature range 30-400 °C under an N2 gas flow, at a heating rate of 5 °C min-1. 
2.8 STRUCTURE DETERMINATION FROM PXRD 
Powder diffraction data were analysed with the software “X’Pert HighScore Plus”. 15-25 
peaks were chosen in the 2θ range 2.5-42.5°, and unit cell parameters were found using 
DICVOL4 or DICVOL algorithms (table 2.8.1 and table 2.8.2). 
 
Table 2.8.1 The obtained salts and a co-crystal solved using X-ray powder diffraction 
Co-former Stoichiometric ratio Product 
COOH
HOOC
 
Fumaric acid, [H2fum] 
1:1 [Hcar] [Hfum] *H2O 
COOH
HOOC
 
Succinic acid, [H2suc] 
1:1 [Hcar] [Hsuc] *H2O 
COOHHOOC
 
Glutaric acid, [H2glu] 
1:1 [Hcar] [Hglu]  
OHHOOC
 
Glycolic acid, [Hgly] 
1:1 [Hcar] [gly]  
OH
COOH
 
Salicylic acid, [Hsal] 
1:1 [Hcar] [sal] *H2O 
COOHHOOC
 
Maleic acid, [H2mal] 
1:1  [Hcar] [Hmal] *H2O 
NH NH
 
Piperazine, pip 
2:1 mel*(pip)0.5 
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Carnosine-fumaric acid salt is described as an example. Identical procedures were used for all 
the systems whose structure was solved from powder diffraction data. This salt has a triclinic 
unit cell with a volume of 418.742 Å3. It was established that in the asymmetric unit one 
molecule of carnosine, fumaric acid and water were present. Space group determination with 
HighScore Plus was not necessary since carnosine has a chiral centre and P1 space group is 
the only possible option in this case. Z=1, Z’=1. The structure was solved by simulated 
annealing using all independent ions and molecules. Simulated annealing, that runs with 
structure fragments, was performed with “EXPO2014” using one carnosine, fumaric acid and 
water molecules. Ten runs for simulated annealing trial were set, and a cooling rate (defined 
as the ratio Tn/Tn-1) of 0.95 was used. Best solutions were chosen for Rietveld refinements, 
which was performed with the software “TOPAS4.1”. A shifted Chebyshev function with 16 
parameters and a Pseudo-Voigt function were used to fit background and peak shape, 
respectively. Soft constraints were applied for all bond distances and angles of the fumaric 
acid molecule, and a planar group restraint was applied to the aromatic ring. An overall 
thermal parameter was adopted for all atoms of the carnosine and fumaric acid molecules. All 
the hydrogen atoms were fixed in calculated positions. Refinement converged with χ2 = 3.718 
and R_wp = 4.760. Figure 2.8.1 shows the experimental, calculated and difference diffraction 
patterns of this salt and figure 2.8.2 shows its structure. 
 
Fig. 2.8.1 Experimental (blue curve), calculated (red curve), and difference (violet curve) powder pattern for  
carnosine-fumaric acid salt. Peak positions are marked in blue. 
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Fig. 2.8.2 Packing diagram of carnosine:fumarate salt detailing hydrogen bond interactions 
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3. RESULTS AND DISCUSSIONS 
3.1 CARNOSINE 
The issue of “Healthy Ageing” has become a significant challenge because of the continuous 
population ageing. Natural antioxidants L-carnosine and melatonin have been successfully 
applied as geroprotectors. They reduce the risk of the development of ageing-related diseases 
that is one the main aspects of healthy ageing. New formulation of the existing APIs is a 
widely used approach to optimize their physico-chemical properties. 
The first step of our research was a polymorph screening (Table 3.1.1). According to the 
Cambridge Structural Database (CSD) only one form of L-carnosine is currently described in 
the literature. In order to accomplish the screening we used a number of organic solvents 
(ethanol, methanol, acetone, acetonitrile, propanol-2, dichloromethane and chloroform) and 
water to dissolve carnosine. The idea was to obtain crystals/powder after the slow evaporation 
from the solvents and to analyse them using X-ray Single Crystal or X-ray Powder 
diffraction. Unfortunately, carnosine appeared to be insoluble in any of the applied organic 
solvents or their mixtures. However, carnosine is highly soluble in water. Thus, we chose the 
organic solvents miscible with water and used their mixture to dissolve carnosine. After the 
evaporation process was complete and the obtained powders were analysed (in none of the 
cases crystals suitable for single crystal analysis were obtained) it was found that in all the 
occasions we had the solid form already described in the literature. 
Table 3.1.1 Carnosine polymorphic screening 
# Solvent Result 
1 H2O The known solid form 
2 Methanol/ H2O The known solid form 
3 Ethanol/ H2O The known solid form 
4 Acetonitrile/ H2O The known solid form 
5 Propanol-2/ H2O The known solid form 
6 Dichloromethane Insoluble 
7 Chloroform Insoluble 
 
The next step of our investigations was to co-crystallize carnosine with ten co-formers from 
different chemical groups (morpholine, piperazine, fumaric acid, quinoxaline, citric acid, 
salicylic acid, 4,4’-bipyridine, trimesic acid, L-asparagine and DABCO) using 1:1 
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stoichiometry. We decided to start with the solution method using water or water/ethanol 
mixture as a solvent (Table 3.1.2). 
Table 3.1.2 Co-crystallisation of carnosine 
# Co-former Solvent Results 
1 Morpholine H2O Starting materials 
2 Piperazine H2O Starting materials 
3 Fumaric acid H2O New salt 
4 Quinoxaline H2O Starting materials 
5 Citric acid H2O Oil 
6 Salicylic acid H2O/EtOH Oil  
7 4,4’-bipyridine H2O/EtOH Starting materials 
8 Trimesic acid H2O/EtOH New salt 
9 L-asparagine H2O Starting materials 
10 DABCO H2O Starting materials 
 
Once again, in none of the cases a single crystal was obtained. Moreover, a reaction with 
citric and salicylic acids resulted into the formation of transparent oils. The other eight 
samples were analysed using X-ray powder diffraction. The diffraction patterns of carnosine 
with fumaric (fig. 3.1.1) and trimesic acids (fig. 3.1.2) showed that the reaction occurred and 
it was complete since there were no peaks belonging to the starting materials.  
Fig. 3.1.1 Powder diffraction data of the salt obtained with carnosine - fumaric acid 
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Fig. 3.1.2 Powder diffraction data of the salt obtained with carnosine - trimesic acid  
Despite the numerous attempts to recrystallise the newly obtained co-crystals/salts we failed 
to do that since they appeared to possess similar solubility characteristics to the ones of 
carnosine. Therefore, we had to use water or water/organic solvents mixtures to dissolve 
them, but no crystals suitable for single crystal analysis were obtained. Furthermore, while 
carnosine-fumarate salt remained stable, the one with trimesic acid separated to the starting 
materials in some of the experiments. In all the other samples we just observed a physical 
mixture of the starting materials. Thus, we conclude that carnosine might react with organic 
acids. 
Obviously, we decided to use a range of various organic acids to check whether our 
conclusion was correct. In order to better understand how carnosine might interact with acids 
it was necessary to predict the possible mechanism of this reaction. Carnosine in water exists 
in a zwitter-ionic form (fig. 3.1.3): the amino-group is protonated by the carboxylic group of 
carnosine.  
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Fig. 3.1.3   L-carnosine: zwitter-ionic form  
The pyridine-type nitrogen of imidazole ring of carnosine molecule (marked in red) is the 
target atom for organic acids in this reaction. Thus, an important issue was to establish 
whether the protonation of this atom occurred and a salt or a co-crystal was formed via 
interaction of this nitrogen with the carboxylate/carboxylic group of the chosen acid. To 
answer this question we decided to apply an “empirical rule” [20]: we calculated the 
difference pKa (base) – pKa (acid), where pKa (base) is the dissociation constant of the 
pyridine-type nitrogen and pKa (acid) – of carboxylic group. If the obtained value was ≥ 2 
then the probability of having a salt as the result of the reaction was higher, and the bigger 
this difference, the greater the chance. In all the cases where we succeeded to obtain new 
substances this value varied from 2.52 to 5.05. We therefore concluded that the NH+⋅⋅⋅COO- 
hydrogen bonding interaction had to be present in the newly obtained salts. 
Using the same evaporation technique with water or water/ethanol mixture as a solvent we 
found out that carnosine in these conditions does not interact with any of the selected amino 
acids (L-glutamic acid, L-asparagine, L-tryptophan) – just a physical mixture of starting 
materials was observed. The majority of the substances obtained by reaction with the acids as 
co-formers appeared to be oils. The oil formation is a relatively common event in co-
crystallisation with organic acids. However, these oils behaved differently upon standing at 
ambient conditions (Table 3.1.3).  
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Table 3.1.3 Carnosine - organic acids interaction 
Stable oils Unstable oils – precipitated 
as starting materials 
Unstable oils – precipitated 
as new salts 
Citric acid L-Glutamic acid Pimelic acid 
Gallic acid Biphenyl-4,4’dicarboxylic 
acid 
Azelaic acid 
Homophthalic acid L-Tryptophan Maleic acid 
Malic acid Nicotinic acid Salicylic acid 
Tricarboxylic acid Isonicotinic acid Benzoic acid (a mixture with 
starting materials) 
Vanillic acid   
Tartaric acid   
Oxalic acid   
Aconitic acid   
 
Based on their behaviour we divided the oils into three main groups. To the first groups 
belong those oils which remained stable at ambient conditions and did not change their 
appearance with time (with oxalic, citric, malic, aconitic, tricarboxylic, vanillic, gallic and 
tartaric acids). The second group consists of the oils that precipitated as a physical mixture of 
starting materials after 10-30 days (with isophthalic, trans-cinnamic, 5-hydroxyisophthalic, 
nicotinic and isonicotinic acids). The last group includes those oils which precipitated as new 
salts – with salicylic, maleic, azelaic and pimelic acids (fig. 3.1.4-3.1.7). 
 
Fig. 3.1.4 Powder diffraction data of the salt obtained with carnosine - salicylic acid 
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Fig. 3.1.5 Powder diffraction data of the salt obtained with carnosine - maleic acid 
 
 
 
Fig. 3.1.6 Powder diffraction data of the salt obtained with carnosine - pimelic acid 
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Fig. 3.1.7 Powder diffraction data of the salt obtained with carnosine - azelaic acid 
Unfortunately, once again no crystals suitable for X-ray single crystal diffraction were 
obtained. All our attempts to recrystallize the new samples were unsuccessful: a combination 
of various solvents with water had to be used to enable the dissolution of the salts that led to 
oil formation. Most likely, this happened due to the lower volatility rate of water in 
comparison to the organic solvents employed. Consequently, organic solvents left the solution 
first and the conditions became the same as the initial ones. It is worth mentioning that 
benzoic acid as a co-former at 1:1 stoichiometry gave a mixture of a new salt and carnosine. 
Increasing the amount of benzoic acid to a 2:1 ratio did not solve this problem: we could still 
observe the peaks of the salt and carnosine; moreover, the peaks of benzoic acid were also 
present in the diffraction pattern (fig. 3.1.8). 
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Fig. 3.1.8 Powder diffraction data of the salt obtained with carnosine - benzoic acid 
Based on the information we got from the experiments mentioned above it is obvious that 
carnosine reacts with dicarboxylic acids (salicylic acid was the only exception). Thus, we 
decided to accomplish the reaction of carnosine with a homologous series of dicarboxylic 
acids HOOC-(CH2)n-COOH (n = 0-8, 10) using the same technique. According to the 
obtained results, we established that there is a noticeable relationship between the length of 
the aliphatic chain of dicarboxylic acids and the products of the reactions (Table 3.1.4). 
Table 3.1.4 Carnosine with linear saturated dicarboxylic acids 
# Acid pKa [36] Solvent Result 
1 Oxalic acid 1.23; 4.19 H2O/EtOH Stable oil 
2 Malonic acid 2.85; 5.05 H2O Stable oil 
3 Succinic acid 4.21;5.41 H2O New salt 
4 Glutaric acid 4.34; 5.41 H2O New salt 
5 Adipic acid 4.41; 5.41 H2O New salt 
6 Pimelic acid 4.51; 5.58 H2O New salt with starting materials  
7 Suberic acid 4.53; 5.50 H2O/EtOH New salt with starting materials  
8 Azelaic acid 4.55; 5.5 H2O New salt with starting materials  
9 Sebacic acid 4.59; 5.59 H2O/EtOH New salt with starting materials  
10 1,12-dodecanedioic acid 5.70; 6.60 H2O/EtOH New salt with starting materials  
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The interaction of carnosine with oxalic and malonic acids (n=0 and n=1, respectively) 
resulted in the formation of quite stable oils. Succinic, glutaric and adipic acids (n=2-4) 
reacted with carnosine producing oils which precipitated in 1-2 weeks into new substances 
(fig. 3.1.9-3.1.11). 
 
Fig. 3.1.9 Powder diffraction data of the salt obtained with carnosine - succinic acid 
 
Fig. 3.1.10 Powder diffraction data of the salt obtained with carnosine - glutaric acid 
 37 
 
 
Fig. 3.1.11 Powder diffraction data of the salt obtained with carnosine - adipic acid 
All the other acids (n=5-8, 10) with carnosine formed oils which precipitated in 1-4 weeks as 
a mixture of new salts with the starting materials. Even pimelic (n=5) and azelaic (n=7) acids, 
which seemed to be pure upon a preliminary analysis using X-ray powder diffraction, 
appeared to be contaminated with the starting materials when they were analysed in a 
capillary (in transmission mode) for a much longer time. 
Taking into account the fact that carnosine possesses antioxidant activity, the following step 
of our research was a trial to test the possibility of its interaction with an acid that will also 
have an analogous biological activity. Actually, we had already obtained such a salt – the one 
with succinic acid. Thus, we decided to try and obtain more salts with other acids with 
antioxidant properties. Ascorbic, glycolic and folic acids were chosen to react with carnosine 
using 1:1 stoichiometry and slow evaporation from solution technique. The interaction of 
carnosine with ascorbic acid resulted into an oil which seemed to be unstable, since bubbles 
of gas trapped in the oil appeared within a few days after oil formation and the amount of 
those bubbles kept increasing. The reaction with folic acid in 1:1 stoichiometry was found to 
be incomplete since the X-ray powder diffraction pattern showed the presence of the peaks of 
folic acid. Consequently, we decided to repeat the experiment using folic acid:carnosine in 
1:2 ratio. In this way we managed to solve the problem. The substance was amorphous (the 
peaks of folic acids and carnosine were not visible in the diffraction pattern), but this 
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behaviour – amorphization upon salt formation - had been observed previously [37], and we 
were not surprised. The most successful result was achieved by the reaction of carnosine with 
glycolic acid: an oil that precipitated into a new salt was obtained (fig. 3.1.12). 
 
Fig. 3.1.12 Powder diffraction data of the salt obtained with carnosine - glycolic acid 
After numerous unsuccessful trials to recrystallize the obtained salts had been made, we 
decided to focus all our efforts on solving structures from X-ray powder diffraction patterns. 
This is still, and usually, a more complicate and time consuming approach, with respect to 
single crystal X-ray diffraction, and represents the frontier of structural solution in molecular 
solid-state and materials chemistry. To achieve this goal it was necessary first to perform 
thermal analyses - thermal gravimetric analysis (TGA) and differential scanning calorimetry 
(DSC). In this way we managed to understand which of the salts might contain solvent in 
their structures, and based on the percentage of solvent lost upon heating (TGA) to find out its 
stoichiometric amount. The figures 3.1.13 and 3.1.14 represent the TGA of succinic and 
glycolic acids correspondingly. They are given as an example of hydrated and anhydrous 
salts. From the TGA data collected for succinic acid-carnosine salt we can notice the loss of 
approximately 2.5% of samples weight at approximately 100 °C. Taking into account the fact 
that melting point of both carnosine and succinic acid are higher than 100 °C and that the salt 
was obtained from water we can conclude that this weight loss occurs due to water 
evaporation. At the same time, for carnosine-glycolic acid salt there is no significant weight 
loss at this temperature range, which indicates that water is absent in this sample.  
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Fig. 3.1.13 TGA of carnosine - succinic acid salt  
Fig. 3.1.14 TGA of carnosine - glycolic acid salt 
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Using TGA and DSC data we were able to show that four salts (with fumaric, maleic, succinic 
and salicylic acids) out of seven contained one water molecule per formula unit. 
The following software was used to fully characterize all seven solids: with “X’Pert High 
Score Plus” and “Dash 3.3.3” the unit cells were determined, whereas “Topas 4.1” and 
“EXPO 2014” were applied for the structure solution. 
The detailed information of the solved structures can be found in the experimental part of the 
thesis (table 2.8.1 and table 2.8.2). Using this characterization approach we managed to 
establish the structures of all the salts but the one with adipic acid. Despite all the numerous 
trials to solve it, we failed to do that so far. It confirms the fact that this approach is a 
complicate one and requires enough patience and skills. The figures 3.1.15-17 shows the 
structures of carnosine salts with glutaric, maleic and salicylic acids. 
 
 
 
Space group  P21 
Unit cell parameters: 
a 8.16     b 38.82     c 5.41 
α 90.0     β 90.37     γ 90.0 
Cell volume  1713.84 
 
 
 
Fig. 3.1.15 Packing diagram of carnosine:glutarate salt detailing hydrogen bond interactions 
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Space group  P 1; Unit cell parameters: a   17.31    b   8.90    c   5.76    α   75.63    β   102.49    γ   98.59 
Cell volume  830.432 
Fig. 3.1.16 Packing diagram of carnosine:maleate salt detailing hydrogen bond interactions 
 
 
 
Space group  P21; Unit cell parameters: a   12.08     b   10.52    c   7.19    α   90.0     β   90.18    γ   90.0 
Cell volume  913.715 
Fig. 3.1.17 Packing diagram of carnosine:salicylate salt detailing hydrogen bond interactions 
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The use of mechanochemistry in our work with carnosine was limited because of the several 
obstacles we faced while using it. First, grinding never worked properly – only physical 
mixtures of the starting materials were detected by X-ray powder diffraction. Second, the use 
of drops of water in kneading experiments usually led to formation of sticky substances which 
did not dry out. The use of some drops of ethanol as a solvent looked more promising. By 
kneading with ethanol we managed to obtain the same product with fumaric acid as we did 
from solution. In the case of salicylic acid, however, the X-ray powder diffraction pattern 
recorded after ball milling for 30 minutes with carnosine showed that the reaction was not 
complete. Similar results were obtained for pimelic and azelaic acids: the intensity of the 
peaks of the starting materials was higher than that measured using solution method. 
Nevertheless, we cannot conclude that mechanochemistry is inapplicable for carnosine – 
organic acid interaction, since more thorough investigations in the field are required. 
The carnosine salts with glycolic (fig. 3.1.18) and succinic acids (fig. 3.1.19) might be of 
higher interest since both of them also possess antioxidant activity and carnosine is used as a 
nutraceutical usually in combination with other antioxidants. Thus, the new formulation of 
carnosine as a salt with an acid possessing antioxidant activity can enhance its biological 
activity and, as a result, enable its usage as a separate drug/nutraceutical. 
 
Space group  P 21 
Unit cell parameters: 
a: 10.372  b: 14.187     c: 
4.689 
α: 90.0      β: 100.75   γ  90.0 
Cell volume  677.848 
 
Fig. 3.1.18 Packing diagram of carnosine:glycolate salt detailing hydrogen bond interactions 
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Space group  P 1 
Unit cell parameters: 
a: 10.964  b: 10.454     c: 4.844 
α: 62.20      β: 106.81   γ  120.89 
Cell volume  420.558 
 
 
 
 
Fig. 3.1.19 Packing diagram of carnosine:succinate salt detailing hydrogen bond interactions 
Furthermore, there is some evidence that glycolic acid [38] and some derivatives of succinic 
acid [39] can act synergistically with other antioxidants. Therefore, it can be interesting to 
investigate biological activity of these salts. Another important issue is the stability of all the 
obtained salts. It was not investigated thoroughly, but their structures remained stable after 
storage for a couple of month at ambient conditions (the obtained X-ray powder diffraction 
patterns were exactly the same as the ones recorded just after the salts were formed). It can be 
beneficial since according to Sigma Aldrich requirements [40] pure carnosine must be stored 
in the freezer at -20 °C. The carnosine salt with folic acid can be even more interesting since 
it is soluble in water whereas folic acid is almost insoluble. Unfortunately, it is impossible to 
solve its structure using X-ray diffraction. Probably, it might be investigated in the future 
using solid-state NMR, IR or Raman techniques. 
3.2 MELATONIN 
The next step of our research dealt with the second antioxidant – melatonin. Based on the 
information from CSD there is only one known polymorph of melatonin so far. Thus, we 
decided to perform a polymorph screening. Unlike carnosine, melatonin is soluble in the 
majority of organic solvents whereas it is hardly soluble in water. Melatonin was dissolved in 
ethanol, methanol, dichloromethane, acetone, chloroform, DMSO and water (table 3.2.1). 
After the solvents evaporated crystals of melatonin were formed in all the vials, but the ones 
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with water and DMSO. The obtained crystals were analysed using X-ray Single Crystal 
diffraction. Unfortunately, in all the cases we dealt with the same already known crystal. 
Afterwards the crystals were ground and analysed using X-ray Powder diffraction. However, 
in all the occasions we had the known solid form. 
Table 3.2.1 Melatonin polymorphic screening 
# Solvents Single crystal Powder X-ray 
1 EtOH the known polymorph --- 
2 MeOH the known polymorph --- 
3 Acetone the known polymorph --- 
4 Dichloromethane the known polymorph  
5 Chloroform the known polymorph --- 
6 H2O --- the known polymorph 
7 DMSO --- the known polymorph 
 
Then we decided to try and co-crystallize melatonin in 1:1 ratio with eight co-formers from 
different chemical groups (morpholine, piperazine, DABCO, fumaric acid, nicotinic acid, 
isophthalic acid and 4,4’-bipyridine) using the solution method with methanol as a solvent 
(Table 3.2.2). 
Table 3.2.2 Melatonin; solution method; solvent - methanol 
# Co-former Single crystal Powder X-ray 
1 Quinoxaline Melatonin crystals Starting materials 
2 Morpholine Melatonin crystals Starting materials 
3 Piperazine Melatonin crystals Starting materials 
4 Fumaric acid --- Starting materials 
5 DABCO Melatonin crystals Starting materials (a new peak 
available) 
6 4,4’-bipyridine --- Starting materials 
7 Isophthalic acid Isophthalic acid 
crystals  
Starting materials 
8 Nicotinic acid Nicotinic acid crystals  Starting materials 
 
Unfortunately, with none of these co-formers we managed to obtain pure co-crystals. 
Furthermore, only with DABCO and piperazine there were some signs of interaction – a few 
peaks different from those of the starting materials were observed in the X-ray powder 
diffraction pattern (fig. 3.2.1).  
 45 
 
Fig. 3.2.1 Powder diffraction data of Melatonin - DABCO interaction in methanol 
All the other diffraction patterns indicated the presence of physical mixtures of the starting 
materials. Thus, we decided to change the solvent. However, with ethanol the results were 
similar to the ones described above, with the only difference that the intensity of the new 
peaks we observed in DABCO and piperazine diffraction patterns became much higher (Fig. 
3.2.2). The next attempt was to use acetone, but this time there was no interaction in all cases. 
 
Fig. 3.2.2 Powder diffraction data of Melatonin – DABCO interaction in ethanol 
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On the basis of these results we decided to change not the solvent, but the method applied. 
The idea was to use ball milling with ethanol as a solvent, since it appeared to be the most 
suitable solvent based on the research described above. This time we succeeded to obtain 
melatonin co-crystals with DABCO and piperazine after milling for 20 minutes. The fact that 
we have new substances was confirmed by X-ray powder diffraction (fig. 3.2.3, 3.2.4). 
 
Fig. 3.2.3 Powder diffraction data of Melatonin – DABCO co-crystallisation in ball mill 
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Fig. 3.2.4 Powder diffraction data of Melatonin – piperazine co-crystallisation in ball mill 
Our task was to solve the structure of the obtained co-crystals. Although numerous attempts 
to recrystallize the obtained co-crystals have been done, it appeared to be really tough to 
obtain a single crystal since, once the co-crystals were dissolved, mainly precipitation of the 
starting materials was observed. Finally, we managed to recrystallize melatonin - DABCO co-
crystal from dichloromethane and to solve its structure using X-ray Single Crystal diffraction 
(fig. 3.2.5). 
Space group  P 21/c 
Unit cell parameters: 
a: 17.685  b: 9.925     c: 9.296 
α: 90.0      β: 103.39   γ  90.0 
Cell volume  1587.31 
 
Fig. 3.2.5 Packing diagram of Melatonin-DABCO co-crystal 
DABCO hydrogen atoms have been omitted for clarity 
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Attempts at recrystallization of melatonin - piperazine co-crystals following the same 
procedure were unsuccessful. So it became obvious that the only way to solve its structure 
was from powder pattern. This time we were helped by the fact that DABCO and piperazine 
molecules are isomorphous. They are similar both in shape and hydrogen bonding propensity, 
and we found out that the obtained co-crystals had very similar unit cells and, finally, it was 
established that the intermolecular interactions in melatonin – DABCO and melatonin – 
piperazine co-crystals was identical (fig. 3.2.6). 
Space group  P 21/c 
Unit cell parameters: 
a: 17.052  b: 9.833   c: 9.335 
α: 90.0      β: 105.10  γ: 90.0 
Cell volume  1511.18 
Fig. 3.2.6 Packing diagram of Melatonin-piperazine co-crystal 
Some of piperazine hydrogen atoms have been omitted for clarity 
Afterwards we tried to co-crystallize melatonin with a number of other co-formers using ball 
milling as the preferred approach. However, we failed to obtain new co-crystals so far (Table 
3.2.3). Though only one of the obtained co-crystals can find a direct application in 
Pharmaceutical industry (DABCO does not belong to the GRAS list), our results confirm the 
reactivity of melatonin in co-crystallization processes, and emphasizes the need to continue 
the search for an improved formulation. 
Table 3.2.3 Melatonin; ball milling; solvent - ethanol 
# Co-former X-ray powder diffraction 
1 L-Glutamine Starting materials 
2 L-aspartic acid Starting materials 
3 4,4'-trimethylenedipiperidine Starting materials 
4 L-Glutamic acid Starting materials 
5 4-aminosalicylic acid Starting materials 
6 e- Caprolactam Sticky, impossible to analyse 
7 L-Histidine Starting materials 
8 L-tryptophan Starting materials 
9 4-aminopyridine Starting materials 
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4. CONCLUSIONS 
It is an indisputable fact that the physicochemical properties of an active pharmaceutical 
ingredient in the solid state play an essential role in a safe, efficient and cost-effective drug 
delivery. Such possible drawbacks as poor dissolution rate, solubility, chemical stability and 
moisture uptake can significantly impact on therapeutic efficacy of a drug. The potential 
effect of those imperfections is difficult to predict: it may result into decrease of market value 
of a drug, loss of market due to lower biological activity than that of competitors, or even 
termination of drug development/production. The design of multi-component solid forms 
(solvates, hydrates, co-crystals, and salts) with specific physico-chemical properties can allow 
to overcome these problems [22].  
The goal of our work was to try and develop new formulations for two geroprotectors with 
strong antioxidant effect – carnosine and melatonin. We managed to obtain seven new salts of 
carnosine and two co-crystals of melatonin. The structures of carnosine salts and melatonin-
piperazine co-crystal were established from X-ray powder diffraction. All the obtained 
carnosine salts and the co-crystal of melatonin with piperazine are potentially useful as drugs 
since they were formed with co-formers that belong to the GRAS list [20].  
The carnosine salts with glycolic and succinic acids might be of higher interest since both of 
them also possess antioxidant activity. This pharmaceutical formulation may be beneficial 
since carnosine is used as a nutraceutical usually in combination with other antioxidants. The 
carnosine salt obtained by interaction with folic acid is also interesting. Besides the fact that 
folic acid is a well-known antioxidant, it is almost insoluble in water at room temperature, 
whereas the obtained salt can be easily dissolved in water. Thus, in this particular case 
carnosine can be employed to improve the solubility of folic acid. Moreover, it can be 
favourable as a co-former since it possesses antioxidant activity and, as a result, both 
components of this salt may act synergistically. The obtained salt appeared to be amorphous 
and this fact did not allow us to try and solve its structure using X-ray diffraction technique. 
Our work is still in progress to characterize the solid products and to investigate their stability 
and solubility properties. Taking into consideration the fact that melatonin has relatively low 
solubility in water, the profound analysis of melatonin-piperazine co-crystal solubility in 
water makes perfect sense. Carnosine is highly soluble in water and therefore there is no need 
to improve this property. However, carnosine requires harsh storage conditions: it has to be 
stored in the freezer at -20 °C. Thus, we plan to study the stability of the obtained salts at 
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ambient conditions. The investigation of biological activity of carnosine salts with glycolic, 
succinic and folic acids could represent a further development of our research. Taking into 
account the influence of carnosine on the solubility rate of folic acid it would be interesting to 
investigate its possible beneficial interaction with other APIs with low water solubility rate. 
Finally, we plan to further investigate the interactions of carnosine and melatonin with 
different co-formers. 
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ANNEXES 
 
Table 1 Carnosine interaction 
# Co-former pKa  Method applied Results 
1 Morpholine  Solution (w) Starting materials 
2 Piperazine  Solution (w) Starting materials 
3 Fumaric acid 3.02 
4.38 
Solution (w) Something new obtained (X-ray powder 
diffraction); Solved from powder pattern 
4 Quinoxaline  Solution (w) Starting materials 
5 Citric acid 3.13 
4.76 
6.39 
Solution  (w) Oil 
6 Salicylic acid 2.97 Solution 
(w/EtOH) 
Oil (precipitated in 2 weeks) 
Something new obtained; 
Solved from powder pattern  
7 4,4’-bipyridine  Solution 
(w/EtOH) 
Starting materials 
8 Trimesic acid 3.12 
3.89 
4.70 
Solution 
(w/EtOH) 
Something new obtained (X-ray powder 
diffraction); no single crystal obtained. 
9 L-asparagine 2.02 Solution (w) Starting materials 
10 DABCO  Solution (w) Starting materials 
11 L-Glutamic acid 2.1 
4.07 
Solution (w) Starting materials 
12 Isophthalic acid 3.46 
4.46 
Solution 
(w/EtOH) 
Oil (precipitated in 3 weeks) – sticky 
substance  
13 Biphenyl-
4,4’dicarboxylic acid 
 Ball Mill Starting materials 
14 Benzoic acid 4.19 Solution (w) Something new obtained (actually, a 
mixture with starting materials in my 
point of view, see the graph) 
15 trans-cinnamic acid 4.44 Solution (w) Oil (precipitated in 3 weeks) 
16 Gallic acid 4.41 Solution (w) Oil 
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17 5-
Hydroxyisophthalic 
acid 
3.41 Solution 
(w/EtOH) 
Sticky substance 
18 Homophthalic acid 3.58 Solution (w) Oil 
19 Isonicotinic acid 4.96 Solution (w) Oil (precipitated in 3 weeks as starting 
materials) 
20 Malic acid 3.40 Solution (w) Oil 
21 Maleic acid 1.9 
6.07 
Solution (w) Solved from powder pattern 
22 Nicotinic acid 4.75 Solution (w) Starting materials 
23 Oxalic acid 1.23 
4.19 
Solution 
(w/EtOH) 
Oil 
24 Pimelic acid 4.71 
5.58 
Solution (w) After analysis using capillary it was 
found out that it is a mixture with 
starting materials 
25 Azelaic acid 4.55 
5.5 
Solution (w) After analysis using capillary it was 
found out that it is a mixture with 
starting materials 
26 Tricarboxylic acid  Solution (w) Oil 
27 L-tryptophan 2.46 
9.41 
Solution (w) Starting materials 
28 Vanillic acid 4.45 Solution (w) Oil 
29 Homophthalic acid 3.58 Ball Mill  Sticky substance (became oil in a day) 
30 Citric acid 3.13 
4.76 
6.39 
Ball Mill Powder, became sticky in a day, became 
oil in 3 days 
31 Oxalic acid 1.23 
4.19 
Ball Mill Powder→sticky substance(30 
minutes)→oil(next morning) 
32 Malic acid 3.40 Ball Mill Sticky substance→Oil (next morning) 
33 4,4’-bipyridine  Ball Mill Starting materials 
34 Tartaric acid  Solution (w) Oil 
35 Aconitic acid 2.80 
4.46 
Solution (w) Oil 
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36 Suberic acid 4.53 
5.50 
Solution (w) A mixture of a new salt and starting 
materials 
37 Sebacic acid 4.72 
5.45 
Solution (w) A mixture of a new salt and starting 
materials 
38 1 12-dodecanedioic 
acid 
5.70 
6.60 
Solution (w) A mixture of a new salt and starting 
materials 
39 Glutaric acid 4.34 
5.22 
Solution (w) Solved from powder pattern 
40 Adipic acid 4.43 
5.41 
Solution (w) New salt. The structure is not solved yet 
41 Succinic acid 4.2 
5.6 
Solution (w) Solved from powder pattern 
42 Ascorbic acid  Solution (w) Oil -destructed in few days (trapped gas 
bubbles in the oil) 
43 Folic acid 1:1  Solution (w) Starting materials 
44 Folic acid 1:1 2.09 
3.37 
Ball Mill (EtOH) 
Ball Mill (w) 
Starting materials – EtOH 
w - amorphous phase with some peaks 
(belong to Folic acid) 
45 Folic acid 2:1  Solution (w) amorphous 
46 Glycolic acid 3.83 Solution (w) Solved from powder pattern 
47 Aspirin  Solution (w) Oil 
48 Pimeliic acid  Ball Mill (EtOH) Partial interaction (30 minutes) 
49 Azelaic acid  Ball Mill (EtOH) Partial interaction (30 minutes) 
50  Salicylic acid  Ball Mill (no 
solvent) 
Starting materials 
51 Salicylic acid  Ball Mill (EtOH) Sticky substance 
52 Salicylic acid  Ball Mill (w) Sticky substance 
53 MgCl2  Solution (w) Oil 
54 NaOH  Solution (w) Starting materials 
55 Sr(NO3)2  Solution (w) Starting materials 
56 CaCl2  Solution (w) Oil/sticky substance 
57 Benzoic acid 2:1  Solution (w) Still a mixture, but also the peaks of 
benzoic acid are observed 
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Fig. 1 TGA of the salt obtained by carnosine – adipic acid interaction 
 
Fig. 2 TGA of the salt obtained by carnosine – azelaic acid interaction 
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Fig. 3 TGA of the salt obtained by carnosine – glutaric acid interaction 
 
Fig. 4 TGA of the salt obtained by carnosine – maleic acid interaction 
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Fig. 5 TGA of the salt obtained by carnosine – pimelic acid interaction 
 
Fig. 6 TGA of the salt obtained by carnosine – salicylic acid interaction 
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Fig. 7 DSC of the salt obtained by carnosine – adipic acid interaction 
 
Fig. 8 DSC of the salt obtained by carnosine – azelaic acid interaction 
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Fig. 9 DSC of the salt obtained by carnosine – glutaric acid interaction 
 
Fig. 10 DSC of the salt obtained by carnosine – glycolic acid interaction 
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Fig. 11 DSC of the salt obtained by carnosine – maleic acid interaction 
 
Fig. 12 DSC of the salt obtained by carnosine – pimelic acid interaction 
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Fig. 13 DSC of the salt obtained by carnosine – salicylic acid interaction 
 
Fig. 14 DSC of the salt obtained by carnosine – succinic acid interaction 
